Literature DB >> 20956376

Jiahuai Han: aflame on inflammation and p38.

Jiahuai Han.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956376      PMCID: PMC2958482          DOI: 10.1083/jcb.1912pi

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


× No keyword cloud information.
The mitogen-activated protein kinases (MAPKs) are a class of serine/threonine kinases that frequently act as fulcrums in the cellular response to stressful stimuli. Jiahuai Han discovered the p38 MAPK (1), and he's spent much of his career characterizing members of the p38 family and the many roles they play in cells (2). Han regards his work on p38 as an important facet of his career, but he says that his real interest is in the cellular response to stress, particularly inflammation (3, 4). His work has touched on many topics related to this subject over the course of his career, and Han has fearlessly pursued the answers to his questions, wherever they lead him. In fact, this pursuit has led him to many different geographical places—from China at the start of his research career, to his pre- and postdoctoral studies in the United States and Belgium (5), a tenured position at The Scripps Research Institute in La Jolla, California, and finally a return to China. We called him at his lab at Xiamen University, Fujian Province, to talk about his many travels. Jiahuai Han

GROWING ABROAD

In Anhui Province, in the middle of China. I grew up during the Cultural Revolution, and resources were scarce. In middle school and high school, we did not learn much. After high school, I spent a year in the countryside because there weren't any other jobs available, so the government just sent people to the countryside to work on farms. Then I got lucky because they began to reopen the exams for entering university. Society was very politically oriented at that time, but the best students were expected to become scientists. So, I took the national exams and entered Peking University in Beijing, which is one of the best universities in China. Honestly, when I went to college and chose to study biology, I didn't really know anything about biology. I didn't even know what molecular biology was. I gradually became more interested in it the longer I studied, but I didn't have any clear plans for what I wanted to do. Once I reached graduate school, I discovered that the condition of the facilities and the research environment were very poor; they hadn't yet been rebuilt after the Cultural Revolution. I realized that if I wanted to do research, I would have to leave the country for more training. In China, I had become interested in cancer, and in trying to find antitumor molecules. Bruce Beutler at UT Southwestern had isolated a protein called tumor necrosis factor (TNF), which I found very interesting, so I wrote to him to see if I could join his lab. I became a visiting student in Bruce's lab, but I completed my PhD in Brussels, Belgium with Georges Huez. Then I went back to UT Southwestern to work with Bruce again, to work on TNF in inflammation. After a while, though, I decided that it was time to move again, so I went to Scripps, where I joined Richard Ulevitch's lab as a senior postdoc.

STATES SOJOURN

Everyone is hard at work in Han's lab. When I was in Bruce's lab, I studied the induction of TNF by inflammatory molecules like lipopolysaccharide (LPS). I focused on the transcriptional and translational regulation of TNF. When I got to Richard's lab, I wanted to look further upstream, to ask what signaling pathways lead to the stimulation of TNF production. I started looking at the signaling pathway downstream of LPS stimulation, and this is how I first encountered p38. I was specifically looking for novel components of that signaling pathway, and when I got a candidate protein, I went ahead and purified it, and it turned out to be p38. It was a fortunate discovery for me, because shortly after discovering p38 I got promoted to assistant professor at Scripps. Basically everything has gone pretty smoothly for me since that time. I subsequently cloned p38, other p38 family members, and a few additional components of the pathway. I should mention that other groups also cloned p38 shortly after us and contributed greatly to the study of p38. When I first found p38, all I knew about it was that it was a phosphorylated protein. After I purified and sequenced it, I realized it was a kinase, and that it would probably have a lot of signaling functions outside of this pathway as well. Of course, now we know that p38 is a MAPK, and that it has many different roles in cells. At first, though, I was mainly interested in its role in TNF production, so I spent a lot of time studying that aspect, but gradually I began to shift my focus away from that question, and I started to branch out into studying p38's other roles. I don't know if that was a good thing or not, but I kept coming up with new questions about the kinase. Even today, a large part of my lab is still working on p38. “We study the signaling pathways involved in the immunological response to stress, and inflammation.” Yes, this is still an important part of my lab's research. People often ask me, what is my focus? Sometimes I have to think about it before I can answer them. Basically, we study the signaling pathways involved in the immunological response to stress, and inflammation. But much of our work touches on subjects outside of inflammation, like cell metabolism or death.

HOME AGAIN

These days, we mostly work on animal models, looking for the in vivo roles of p38. There are four members of the p38 family, so we have a lot of work to do characterizing the functions of the different isoforms. Sometimes they have really quite different functions; for example, the p38-δ isoform seems to play a role in glucose homeostasis, and is connected with the insulin system. Other isoforms, like p38-α and p38-γ, are important for cellular senescence, which is a major mechanism for protecting against tumorigenesis. We are studying p38-α most closely, and we have found that it can modulate the activity of the tumor suppressor p53. Han training students in his lab. Actually, that is a very long story; we worked on that one for some time. We started working on it because of our interest in TNF. Certain cells, when treated with TNF, undergo necrotic cell death. The molecular basis of necrosis is poorly defined right now, but the most practical definition for our study is that it is a form of cell death that, unlike apoptosis, does not involve caspases. We wanted to see if we could find a key molecule that is important for necrosis. We had been working on this problem for a while when I heard about a paper that another group had published, which claimed that TNF-treated NIH-3T3 cells didn't undergo apoptotic cell death, because if you blocked caspases, the cells would still die. I thought this was interesting because, generally speaking and also in our hands, TNF treatment of NIH-3T3 cells causes apoptosis, and does involve caspases. So we got some of these necrotic NIH-3T3 cells, and we compared their gene expression profile to our apoptotic NIH-3T3 cell line. We found very few genes that were different, but the necrotic NIH-3T3 cells expressed a gene called Rip3. At that time, RNAi technology was just becoming available, so we knocked down Rip3 in the necrotic NIH-3T3 cells, and found that now they started to die by apoptosis. Later, we were able to show that the mechanism by which Rip3 causes cell death involves modulating metabolism and reactive oxygen species production. That is one of the reasons I moved back to China in 2007. Partly I just felt that it was time for a change of scenery, to keep things interesting. But I also wanted to have a big laboratory so that I could follow up on everything we find, and continue to expand on it. I thought it would be easier to have a big laboratory in China—although I still have a partial appointment at Scripps to finish up the work I started while I was there. “I wanted to have a big laboratory so that I could follow up on everything.” The main difference between working in China and working at Scripps is that here, all the work in my lab is done by university students and graduate students. On one hand, that is very nice because their salaries are paid by the university, and the students here work very hard. That means I can have many people working on different projects, and I can get much more done with less money. On the other hand, there are not many postdocs in China; even though the research environment in China is now much stronger than it was, many Chinese students still go abroad for their postdocs. So, I basically have to train everyone up from the beginning. That's OK with me, though, because I think it's fun working with students.
  5 in total

1.  PRAK is essential for ras-induced senescence and tumor suppression.

Authors:  Peiqing Sun; Naoto Yoshizuka; Liguo New; Bettina A Moser; Yilei Li; Rong Liao; Changchuan Xie; Jianming Chen; Qingdong Deng; Maria Yamout; Meng-Qiu Dong; Costas G Frangou; John R Yates; Peter E Wright; Jiahuai Han
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

2.  Interactive effects of the tumor necrosis factor promoter and 3'-untranslated regions.

Authors:  J Han; G Huez; B Beutler
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

3.  RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis.

Authors:  Duan-Wu Zhang; Jing Shao; Juan Lin; Na Zhang; Bao-Ju Lu; Sheng-Cai Lin; Meng-Qiu Dong; Jiahuai Han
Journal:  Science       Date:  2009-06-04       Impact factor: 47.728

4.  Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages.

Authors:  Young Jun Kang; Sung Ouk Kim; Shigeki Shimada; Motoyuki Otsuka; Alim Seit-Nebi; Byoung S Kwon; Tania H Watts; Jiahuai Han
Journal:  Nat Immunol       Date:  2007-05-13       Impact factor: 25.606

5.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.

Authors:  J Han; J D Lee; L Bibbs; R J Ulevitch
Journal:  Science       Date:  1994-08-05       Impact factor: 47.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.